Objectives. Hyperuricaemia has been linked to atherosclerosis; however, there is limited evidence about its association with arterial stiffness and cardiac hypertrophy, which are associated with adverse cardiovascular outcomes. We studied the association of hyperuricaemia with an increased risk of arterial stiffness and cardiac hypertrophy in a population participating in a health-screening programme.
Introduction
Evidence shows that hyperuricaemia is associated with cardiovascular disease. High levels of serum uric acid (SUA) were predictive of unfavourable outcomes in patients with chronic heart failure [1] , coronary artery disease [2] and stroke [3] . In individuals with high cardiovascular risk, most epidemiological studies reported an independent role for hyperuricaemia in cardiovascular diseases and mortality [4, 5] . A recent meta-analysis suggested that hyperuricaemia was significantly positively associated with the incidence of stroke [relative risk (RR) 1.41; 95% CI 1.05, 1 .76] and with mortality (RR 1.36; 95% CI 1.03, 1.69) [6] . The Taiwan Chin-Shan Community Cardiovascular Cohort Study also reported that timedependent uric acid was associated with hazard ratios of 1.43 (95% CI 1.10, 1.87) and 1.22 (95% CI 1.03, 1.44) for coronary heart disease in men and women, respectively [7] .
Cardiac hypertrophy is the heart's response to increased biomechanical stress. Evidence suggests that cardiac hypertrophy is not just a compensatory response, but a tenuous balance between adaptive characteristics and deleterious structural alterations [8] . Moreover, sustained cardiac hypertrophy often progresses to heart failure [9] . Pressure overload and humoral and genetic factors contribute to the development of cardiac hypertrophy [10] . Since arterial stiffness increases afterload and end-diastolic stress, which are the main determinants of cardiac hypertrophy, there may be a link between arterial stiffness and cardiac hypertrophy.
Of late, the association between arterial stiffness and cardiovascular mortality has been highlighted [11] . Increased arterial stiffness has also been independently associated with impaired systolic and diastolic function [12] . Arterial stiffness can be assessed in a clinical setting by using several techniques, such as pulse wave velocity (PWV), wave reflection and applanation tonometry; among them, PWV is an established indicator of arterial stiffness [13, 14] and a marker of vascular damage [15] . Arterial stiffness results from contributing factors such as atherosclerosis and vascular wall calcification and causes an increase in the conduction velocity of an impulse along the vessel length, which can be measured by PWV. Brachial-ankle PWV (baPWV) is a clinic-based device that has good validity [16] and has been widely applied in the screening of subjects at risk of cardiovascular diseases.
Hyperuricaemia has been linked to atherosclerosis, but there is limited evidence of its association with arterial stiffness and cardiac hypertrophy, which increase the risk of adverse cardiovascular outcomes. A study found that SUA was independently associated with left ventricular mass, and that the combination of hyperuricaemia and left ventricular hypertrophy (LVH) was a powerful independent predictor of cardiovascular endpoints, including myocardial infarction, angina pectoris, congestive heart failure, cerebral infarction and transient cerebral ischaemia [17] .
Our aim was to determine if hyperuricaemia was associated with an increased risk of arterial stiffness and cardiac hypertrophy in a large population participating in a health-screening programme at Chang Gung Memorial Hospital (CGMH) from 2005 to 2007.
Methods

Study population
We analysed a population of subjects who had undergone health screening at CGMH from 2005 to 2007. In other words, a cross-sectional study design was used, in which all measurements were obtained at the same time. Since some medications alter serum uric levels, subjects were excluded if they had received a diagnosis of gout [International Classification of Diseases, Ninth Revision (ICD-9) codes 2740-9] before or as a result of health screening. The diagnosis of gout was based on the physician's documentation. For subjects with multiple visits, data from the first visit were used for this study. The study has been approved by the Institutional Review Board of the CGMH (approval number: 98-2004B). The present study was conducted with full compliance with local, national, ethical and regulatory principles. Informed patient consent was obtained before health screening. Data that could identify participants were removed to ensure anonymity during the entire study process.
All blood specimens obtained in this study were sent to the clinical laboratory at CGMH, which is certified by the College of American Pathologists. Serum creatinine, blood urea nitrogen, albumin, uric acid, plasma glucose and other biochemical data were measured using a Hitachi 7470 autoanalyzer (Hitachi, Tokyo, Japan).
Internal and external quality control procedures for biochemical data yielded consistently satisfactory results. External quality control was ensured by observing the guidelines from the College of American Pathologists and the National Quality Control Program of the Government of Taiwan. SUA was measured using the spectrophotometric uricase method, whereas creatinine was measured using the Jaffe method. The coefficient of variation of repetitive determinations of SUA of known samples throughout the year (the central laboratory of CGMH performs quality control and assessment periodically and the coefficient of variation is representative data during the study period, which is consistent for this period) at this hospital laboratory was 41.8%. Proteinuria was done by dipstick urinalysis and reported semiquantitatively, as +1-4 (if positive) or negative. Hyperuricaemia was defined as an SUA level >7.7 mg/dl (458.0 mmol/l) in men and 6.6 mg/dl (392.6 mmol/l) for women [18] . Metabolic syndrome was defined by using the modified adult treatment panel III (ATP III) criteria, according to the recommendations of the Health Promotion Bureau in Taiwan [19] . Hypertension was defined as systolic blood pressure (SBP) >140 mmHg or diastolic blood pressure (DBP) >90 mmHg [20] .
Arterial stiffness was measured as baPWV (cm/s) using a Colin non-invasive vascular screening device (model BP-203 RPE II; Colin Medical Technology, Komaki, Japan). After 5 min of resting in the supine position, the subject's bilateral arm and ankle blood pressure and pulse volumes in the brachial and posterior tibial arteries were recorded. Although baPWV values were measured bilaterally, the higher value was used for the analysis. Abnormal baPWV was defined as the highest quartile of values in subjects [21] ; in the present study, the cut-off value was 1671 cm/s for men and 1683 cm/s for women. The cardiologists did the baPWV and interpreted the electrocardiography, while a radiologist examined the plain chest radiograph. Cardiac hypertrophy was defined as the presence of cardiomegaly (cardiothoracic ratio >0.5) on a standard plain chest radiography in a standing position or LVH on ECG using the Sokolow-Lyon criteria: R wave in V5-V6 plus S wave in V1 >35 mm.
Statistical analysis
Summary statistics are expressed as percentages for categorical data, mean (S.D.) for approximately normally distributed continuous variables and median and interquartile range for skewed continuous variables. Comparison between groups was made using the chi-square test for categorical data and analysis of variance or the MannWhitney U-test for continuous data. Multiple comparisons were not made. As the linearity between uric acid and PWV is doubtful and their linear association is cumbersome for clinical interpretation, dichotomous classification for uric acid was used. Polychotomous logistic regression using forward selection was used to determine factors affecting the risk of arterial stiffness alone, cardiac hypertrophy alone or coexisting abnormal baPWV and cardiac hypertrophy. The forward selection process added factors sequentially to the polychotomous logistic regression based on the likelihood ratio tests that compared the simpler model with the more complex one. A two-sided P < 0.05 was considered statistically significant. All analyses were done using SPSS statistical software, version 17.0 (SPSS, Chicago, IL, USA).
Results
Clinical characteristics of subjects
A total of 9375 subjects were included in the analysis, of which 1363 (14.5%) had hyperuricaemia. The mean age was 55.6 (12.4) years; subjects with hyperuricaemia [57.6 (13.2) years] were older than normouricaemic ones [55.3 (12.2) years]. Men had significantly higher SUA than women [6.8 (1.9) vs 5.5 (1.7) mg/dl; P < 0.001]. Subjects with hyperuricaemia were more likely to have hypertension [odds ratio (OR) 1.77; 95% CI 1.57, 2.00], metabolic syndrome (OR 2.79; 95% CI 2.46, 3.17) and proteinuria (OR 2.67; 95% CI 2.11, 3.37). In the hyperuricaemia group, fasting and post-prandial glucose, triglyceride, total cholesterol, low-density lipoprotein cholesterol and high-sensitive CRP (hsCRP) were significantly higher, and high-density lipoprotein (HDL) cholesterol was significantly lower. Hyperuricaemia was associated with ORs (95% CI) of 1.68 (95% CI 1.49, 1.88), 1.97 (95% CI 1.74, 2.24) and 2.34 (95% CI 2.08, 2.64) for hyperglycaemia, hyperlipidaemia and high hsCRP, respectively. Table 1 compares the prevalence of abnormal metabolic components, proteinuria, high hsCRP between those with normouricaemia and hyperuricaemia for men and women. In general, these ORs were higher in women than in men. We classified the subjects into four categories of dependent variables: those with normal baPWV and no cardiac hypertrophy (men, n = 3391; women, n = 2824), with abnormal baPWV alone (men, n = 1005; women, n = 728), with cardiac hypertrophy alone (men, n = 443; women, n = 414) and with coexisting abnormal baPWV and cardiac hypertrophy (men, n = 235; women, n = 335). We performed polychotomous logistic regression with forward selection to determine factors affecting the risk of abnormal baPWV alone, cardiac hypertrophy alone or coexisting abnormal baPWV and cardiac hypertrophy. Tables 3  and 4 show the results in men and women, respectively. In men, hyperuricaemia was associated with abnormal baPWV alone (OR 1.33; 95% CI 1.08, 1.65) and with coexisting abnormal baPWV and cardiac hypertrophy (OR 1.75; 95% CI 1.24, 2.47), but not with cardiac hypertrophy alone, after adjusting for age, proteinuria, hsCRP, ABI or number of metabolic syndrome components present. In women, hyperuricaemia was significantly associated with coexisting abnormal baPWV and cardiac hypertrophy (OR 1.41; 95% CI 1.04, 1.91), but not abnormal baPWV alone or with cardiac hypertrophy alone, after adjusting for age, proteinuria, hsCRP, ABI or number of metabolic syndrome components present.
Discussion
This study investigated the association of hyperuricaemia with abnormal baPWV and cardiac hypertrophy. We found that baPWV, a surrogate marker of arterial stiffness, was significantly higher in those with hyperuricaemia, as was the prevalence of cardiac hypertrophy. Consistently, previous studies found that SUA level was associated with left ventricular mass [17] and that each S.D. increase in SUA increased the risk of cardiac hypertrophy by 75% [22] . This study also showed that hyperuricaemia was associated with coexisting abnormal baPWV and cardiac www.rheumatology.oxfordjournals.org hypertrophy, but not associated with either of those alone, independent of the presence of traditional cardiovascular risk factors such as metabolic syndrome, proteinuria or high hsCRP. These results imply that there is a role for uric acid in the link between arterial stiffness and cardiac hypertrophy.
The associations between SUA level and electrocardiographic abnormalities [23] and cardiac hypertrophy [24] have been reported; however, only limited information exists about arterial changes in people with hyperuricaemia. Tavil et al. [25] reported that carotid artery intima-media thickness was higher among those with hyperuricaemia than those who were normouricaemic subjects. Ishizaka et al. [21] noted that subjects in the highest quartile of SUA level had an OR of 2.4 for arterial stiffness. Our study showed that mean baPWV progressively increased with higher quartiles of SUA level in subjects without cardiac hypertrophy, and to a lesser extent in those with cardiac hypertrophy.
Cardiac hypertrophy is common in patients with arterial hypertension and is known to increase the risk of cardiovascular disease [26] . Haemodynamic factors, particularly end-diastolic stress, are the best understood stimuli for cardiac hypertrophy [27] . Arterial stiffness is an important haemodynamic parameter that might contribute to cardiac hypertrophy [28, 29] . Arterial stiffness increases after load, augments left ventricular mass, reduces coronary perfusion and may result in poorer cardiovascular outcomes [30, 31] . This study supports the hypothesis that hyperuricaemia is an independent risk factor for coexisting abnormal baPWV and cardiac hypertrophy. Multivariate analysis indicated that the risk for abnormal baPWV due to hyperuricaemia in the absence of cardiac hypertrophy was inconsistent between sexes. As subjects having abnormal baPWV but no cardiac hypertrophy most likely represented those with early-stage arterial stiffness, the absence of an association between hyperuricaemia and abnormal baPWV alone suggests that, among women, there are important causative factors other than SUA level. In this study, the magnitude of the risk due to age and the number of metabolic syndrome components present were markedly higher in women than in men. A previous study showed that baPWV in women increases quadratically during their sixth decade of life, indicating that menopause plays an important role in the progression of arterial stiffness [32] . Since menopause hastens the progression of atherosclerotic cardiovascular diseases [33] , the progression of arterial stiffness may differ in men and women, as shown in this study and in a study by Tomiyama et al. [32] . The present findings suggest that although the presence of hyperuricaemia is not important in the early stages of arterial stiffness in women, its relative importance increases as arterial stiffness progresses, particularly when cardiac hypertrophy develops. In contrast, hyperuricaemia is important throughout the development and progression of arterial stiffness in men.
An animal study indicated that mild hyperuricaemia causes hypertension and renal injury through a crystal-independent mechanism, via stimulation of the renin-angiotensin system and inhibition of neuronal nitric oxide synthase [34] . Uric acid is capable of inducing endothelial dysfunction by decreasing the production of nitric oxide in endothelial cells [35, 36] and by stimulating the proliferation of vascular smooth muscle cells [37] . A recent clinical study observed that uric acid-lowering therapy resulted in a reduction in blood pressure and decreased systemic vascular resistance [38] . Furthermore, SUA was found to be closely related to the intra-renal reninangiotensin system [39] and it was also a predictor for heart failure independent of B-type natriuretic peptide [40] . Taken together, these findings suggest that hyperuricaemia induces arterial stiffness, which then promotes cardiac hypertrophy.
A major strength of this study was that it analysed data from a large sample of community-dwelling adults, and that the findings can thus be generalized. The sample size of 5000 (5000 for each sex) in this study can achieve 99% power to detect an effect size (W) of 0.0700 using 3 degrees of freedom chi-square test with a significance level () of 0.05. Moreover, the nature of the health-screening programme ensures completeness of the relevant clinical and laboratory data. However, the drawbacks of this study are its cross-sectional design, recall bias on remote gouty attacks and the absence of information on concomitant medication. For instance, the use of cardioprotective treatment, in particular diuretics, may confound our findings. Further research needs to examine how concomitant medication affects the association of uric acid in those with and without disturbed high baPWV or cardiac hypertrophy, or both. To our knowledge, this study is the first to identify an association of SUA with arterial stiffness and cardiac hypertrophy. In addition, this study has added to the limited understanding of the role of SUA in the progression of arterial stiffness to cardiac hypertrophy.
In conclusion, we showed that arterial stiffness, as measured by baPWV, increased significantly in people with hyperuricaemia. In addition, hyperuricaemia was associated with coexisting abnormal baPWV and cardiac hypertrophy, independent of traditional cardiovascular risk factors. These results suggest that hyperuricaemia, along with other risk factors related to atherosclerosis, contributes to the development of cardiac hypertrophy by increasing arterial stiffness. The question of whether differences in sex exist in the development and progression of arterial stiffening will need further investigation.
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